Effect of Antithrombotic Treatment in Patients With Both Coronary Heart Disease and Atrial Fibrillation
ACHDAF
1 other identifier
observational
1,000
1 country
1
Brief Summary
The optimal antithrombotic treatment for Coronary Heart disease (CHD) patients combined with Atrial Fibrillation (AF) is unresolved at present. Although the European and American guidelines have given a hand for us, there is absence of real-world data on the safety and efficacy of antithrombotic therapy in Asian populations. Only a few clinical trials are available to guide difficult decision on antithrombotic therapy in patients with combined AF and CHD，the investigators highlight the need for the rapid development of clinical trials to close the large gaps in evidence. This research aims to know the real-world use of antithrombotic treatment and clinical prognosis in Coronary Heart Disease patients complicated with Atrial Fibrillation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2017
CompletedFirst Submitted
Initial submission to the registry
February 9, 2017
CompletedFirst Posted
Study publicly available on registry
February 13, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedDecember 12, 2019
March 1, 2019
2.8 years
February 9, 2017
December 11, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Thromboembolism
including ischemic stroke and systemic embolization
1 year
Secondary Outcomes (3)
Hemorrhage
1 year
Major Adverse Cardiovascular Events(MACE)
1 year
A composite outcome
1 year
Eligibility Criteria
patients with coexisting coronary heart disease and atrial fibrillation
You may qualify if:
- Patients with chest pain and a significant lesion \>50% angiographically.
- Patients with a documented AF as confirmed by 12 leads ECG or Holter ECG.
You may not qualify if:
- Rheumatic valvular disease.
- Contraindications to oral anticoagulation.
- Combined with other serious diseases with a life expectancy \< 1 year.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Henan Provincial People's Hospital
Zhengzhou, Henan, 450000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Changyu Gao, PhD
Henan Provincial People's Hospital
- PRINCIPAL INVESTIGATOR
You Zhang, PhD
Henan Provincial People's Hospital
- PRINCIPAL INVESTIGATOR
Lili Wei, MD
Henan Provincial People's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 9, 2017
First Posted
February 13, 2017
Study Start
February 1, 2017
Primary Completion
December 1, 2019
Study Completion
December 1, 2019
Last Updated
December 12, 2019
Record last verified: 2019-03
Data Sharing
- IPD Sharing
- Will not share